First real success for anti-HIV gel: A new start for HIV microbicides?

Future Microbiology

Volumn 5, Issue 11, 2010, Pages 1621-1623

  Ariën, Kevin K ^a   Vanham, Guido ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Africa; CAPRISA 004; gel; HIV; microbicides; tenofovir; transmission

Indexed keywords

C31G; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; NEVIRAPINE; NONOXINOL 9; PC 515; PRO 2000; SAVVY; TENOFOVIR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GEL; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

ADENINE; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; SEXUALLY TRANSMITTED DISEASES, VIRAL; SOUTH AFRICA; TREATMENT OUTCOME; VAGINAL CREAMS, FOAMS, AND JELLIES; YOUNG ADULT;

EID: 78650219266     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.129     Document Type: Review

References (23)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (329)5996, 1168-1174 (2010).
2. Kreiss J, Ngugi E, Holmes K et al.: Effcacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268(4), 477-482 (1992).
3. Van Damme L, Ramjee G, Alary M et al.: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360, 971-977 (2002).
4. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL: A controlled trial of nonoxynol 9 flm to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 339(8), 504-510 (1998).
5. Peterson L, Nanda K, Opoku BK et al.: SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo controlled trial in Ghana. PLoS One 2(12), e1312 (2007).
6. Feldblum P, Adeiga A, Bakare R et al.: SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 3(1), e1471 (2008).
7. Halpern V, Ogunsola F, Obunge O et al.: Effectiveness of cellulose sulphate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria. PLoS One 3(11), e3784 (2008).
8. Van Damme L, Govinden R, Mirembe F et al.: Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463-472 (2008).
9. Skoler-Karpoff S, Ramjee G, Ahmed K et al.: Effcacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372, 1977-1987 (2008).
10. Nunn A, McCormack S, Crook A, Pool R, Rutterford C, Hayes R: Microbicides Development Programme: design of a Phase III trial to measure the effcacy of the vaginal microbicide PRO 2000/5 for HIV prevention. Trials 10, 99 (2009).
11. Abdool Karim S, Coletti A, Richardson B et al.: Safety and effectiveness of vaginal microbicides buffer gel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial. Presented at: 16th CROI. Montreal, Canada, 8-11 February 2009.
12. MDP: HIV 'Prevention' Gel PRO 2000 Proven Ineffective. MDP Press Release. 20 July 2010.
13. Gali Y, Ariën KK, Praet M et al.: Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J. Virol. Methods 165(2), 186-197 (2010).
14. Gali Y, Delezay O, Brouwers J et al.: In vitro evaluation of viability, integrity and infammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. DOI:10.1128/ AAC.00456-10. Antimicrob. Agents Chemother. (2010) (Epub ahead of print).
15. Check E. HIV trial doomed by design, say critics. Nature 448(7150), 110-111 (2007).
16. Barditch-Crovo P, Deeks SG, Collier A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodefciency virus-infected adults. Antimicrob. Agents Chemother. 45(10), 2733-2739 (2001).
17. Cranage M, Sharpe S, Herrera C et al.: Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5(8), e157 (2008).
18. Denton PW, Estes JD, Sun Z et al.: Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5(1), e16 (2008).
19. Nel AM, Coplan P, van de Wijgert JH et al.: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 23(12), 1531-1538 (2009).
20. Nel A, Smythe S, Young K et al.: Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defc. Syndr. 51(4), 416-423 (2009).
21. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW: Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J. Acquir. Immune Defc. Syndr. 55(2), 161-169 (2010).
22. Selhorst P, Terrazas-Aranda K, Michiels J et al.: Assessing HIV-1 cross-resistance in vitro against RTI-based microbicides currently under development. Presented at: International Microbicides Conference. Pittsburgh, PA, USA, 22-25 May 2010.
23. Selhorst P, Vazquez AC, Terrazas-Aranda K et al.: In vitro HIV-1 cross-resistance against RTI-based microbicides. Presented at: International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies. Dubrovnik, Croatia, 8-12 June 2010.